An orally bioavailable inhibitor of tyrosine kinase, with potential anti-inflammatory and antineoplastic activities. Upon oral administration, tyrosine kinase inhibitor TL-895 targets, binds to, and inhibits tyrosine kinase. This may result in the inhibition of tumor angiogenesis and cell proliferation, and the inhibition of immune-mediated inflammatory processes. Tyrosine kinases are upregulated in many tumor cells and play important roles in tumor cell proliferation and metastasis. In addition, they play important roles in the activation of leukocytes and in many immune-mediated inflammatory and autoimmune conditions.